glp 1 agonists moa GLP-1 For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Mechanism of action of GLP-1

A dose of intravenous erythromycin (200-300mg) promotes gastric motility [9] , while metoclopramide increases digestive system movements [10]

Reflux matters

[10] SURMOUNT-1 : Tirzepatide for the treatment of obesity produced ~2022% weight loss over 72 weeks, among the largest effects seen in pharmacologic obesity treatment

Last reviewed: June 10, 2026 Last updated: June 10, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

Think about it Would you have started Ozempic if your doctor said, "Oh, and there's a good chance you'll lose your hair in clumps starting around month four"

While the role of the gut microbiome is not fully understood in the development and progression of pediatric MASLD, it is worth mentioning that alterations in the gut microbiome can influence genes involved in lipogenesis within the liver [16]